LGVN earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -0.54. Updated 2026-07-23.
Longeveron (LGVN) Research Hub
Longeveron (LGVN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 7.33 USD (+11.40%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.54, market cap 0.01B. This hub links to the full technical, earnings and options research available for LGVN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.33 USD (+11.40%) |
| 52-week range | 5.86 USD – 8.8 USD |
| Trend regime | Range |
| 14-day RSI | 47.2 (Neutral) |
| Trailing P/E | -0.54 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for LGVN
Covered Call on LGVN: how it works, illustrative setup around the real 7.33 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LGVN: how it works, illustrative setup around the real 7.33 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LGVN: how it works, illustrative setup around the real 7.33 USD price, max profit/loss, breakeven and when to use it. Educational.
LGVN technical analysis: range, last 7.33 USD, RSI 47.2, 52w range 5.86 USD–8.8 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is LGVN in?
Longeveron (LGVN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LGVN in an uptrend or downtrend?
As of 2026-09-11, LGVN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LGVN's trailing P/E ratio?
LGVN's trailing P/E is -0.54, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does LGVN next report earnings?
LGVN is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.19 USD.